Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

ABSTRACT

Introduction: Perception of illness varies among individuals and psoriasis of the same severity can be perceived in different ways by patients, making it essential to evaluate quality of life (QoL) since it can provide information on the impact of the disease on the patient’s overall well-being. The use of patient-reported outcomes in clinical trials provides the ability to integrate objective clinical assessment with the patient’s perception of their own state of health.

Areas covered: The introduction of anti-IL17 agents in clinical practice has given patients the possibility to achieve a PASI90 response (almost clear skin) or even higher (complete clear skin) in the majority of patients. There is accumulating evidence in support of PASI90 response as the new standard goal for therapy based on its greater correlation with health-related QoL. The present review summarizes current knowledge of the effects of secukinumab on the QoL of patients with psoriasis using patient-reported outcome measures.

Expert Opinion: Secukinumab, the first approved drug of this new class, has fully reached a new therapeutic paradigm not only in terms of clinical efficacy, but also in terms of patient satisfaction and self-rated health.

KEYWORDS:

• Illness perception
• quality of life
• patient-reported outcomes
• secukinumab
• self-rated health

Article highlights

• It is becoming increasingly essential to evaluate QoL in patients with psoriasis as it gives vital information about the patient’s overall well-being and efficacy of treatment.

• Patient-reported outcomes can integrate objective clinical assessment with the patient’s perception of their own state of health.

• The introduction of anti-IL17 agents has allowed for the majority of patients to achieve a PASI90 response or even higher, and as such PASI90 is now becoming the new goal for therapy.

• Secukinumab, the first approved drug of the new class of anti-IL17 agents, has fully reached a new therapeutic paradigm in terms of clinical efficacy, patient satisfaction, and self-rated health.

This box summarizes key points contained in the article.

Acknowledgments

We thank Patrick Moore, who provided editorial assistance on behalf of Health Publishing & Services Srl. This unconditional support was funded by Novartis Farma SpA.

Declaration of interest

L Bianchi has served as a speaker and as a consultant for Abbvie, Novartis, Janssen-Cilag, Pfizer, UCB, and Leo-Pharma outside the submitted work. The other authors have no conflicts of interest to declare. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewers disclosure

A reviewer on this manuscript has disclosed receiving research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation; They have also consulted for others through Guidepoint Global, Gerson Lehrman and other consulting organizations; They are a founder and majority owner of www.DrScore.com; They are a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Author contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Additional information

Funding

This paper was not funded.